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Staphylococcal cassette chromosome mec (SCCmec) types and Panton-Valentine leukocidin (PVL) gene
carriage were compared among suspected community-associated methicillin-resistant Staphylococcus aureus
MRSA (CA-MRSA) and health care-associated MRSA (HA-MRSA) isolates. CA-MRSA isolates carried the
SCCmec type IV complex, and most were PVL positive. The HA-MRSA isolates carried the SCCmec type II
complex and did not harbor the PVL genes.
Methicillin-resistant Staphylococcus aureus (MRSA) contin-
ues to be a major cause of both health care-associated and
community-associated infections. The resistance of the organ-
ism is due to acquisition of the methicillin resistance gene
mecA, carried by the staphylococcal cassette chromosome mec
(SCCmec). Recently, numerous studies have reported the emer-
gence of community-associated MRSA (CA-MRSA) within the
hospital setting, posing a significant public health threat (1, 2,
12). CA-MRSA isolates have several distinguishing character-
istics that make them distinct from nosocomial strains. First,
health care-associated MRSA (HA-MRSA) strains tend to
carry SCCmec types I, II, and III, while the type IV element is
generally carried by CA-MRSA (9, 10, 11, 16). Second, the
Panton-Valentine leukocidin (PVL) genes have been demon-
strated primarily among CA-MRSA strains (4, 8, 13, 14). PVL
is an S. aureus-specific exotoxin often associated with severe
skin infections and necrotizing pneumonia (4); however, its
role as a virulence determinant has recently been disputed
(15). Finally, CA-MRSA strains typically demonstrate resis-
tance to fewer antimicrobials than strains acquired within hos-
pitals (7). We sought to characterize the SCCmec types of
isolates submitted for strain typing and, among these strains, to
determine the prevalence and distribution of the PVL exo-
toxin. Antimicrobial susceptibility patterns were also compared
among strains.
The original specimens used in this study were collected
from central Florida hospitals during a 9-month period from
March 2005 through November 2005 among two patient popula-
tions (institutional review board approval number 101457D).
Surveillance specimens consisting of either nasal or rectal spec-
imens were collected upon admission from patients considered
to be at high risk for MRSA colonization. Specimens collected
from inpatients for the purpose of infection control investiga-
tions included tracheal aspirate, skin/wound/abscess, blood,
and cerebrospinal fluid (CSF) samples. Only one isolate from
each patient was included in the study.
Strain typing was performed using the DiversiLab strain typing
system (Bacterial Barcodes, Inc., Athens, GA). Genomic DNA
was extracted (Ultra Clean microbial isolation kit; MoBio Lab-
oratories, Carlsbad, CA) and amplified by repetitive sequence-
based PCR (rep-PCR) methodology using the Staphylococcus
kit for DNA fingerprinting (6). Analysis was performed using
the Web-based DiversiLab software, which determines dis-
tance matrices to create dendrograms. Sample relationships
were designated as follows: indistinguishable (no band differ-
ences), related (one band difference), or different (two or more
band differences).
Sixty isolates were screened by real-time PCR to confirm the
identification of S. aureus (femA) and the presence of the mecA
gene (5). Traditional PCR, targeting the mec gene complex
and the ccr gene complex, was then performed on all samples
to identify SCCmec elements I to IV, including subtypes IVa
and IVb (9). Controls were S. aureus isolates containing SCCmec
types I to IV (including subtypes IVa and IVb). Finally, the PVL
locus was detected by TaqMan PCR (3), using a 0.5 McFarland
standard suspension of the organism added directly to the
reaction mixture.
The rep-PCR patterns clustered the majority of isolates into
four major clonal groups or clusters (clusters A, B, C, and D)
as demonstrated in Fig. 1. Within these major clusters, samples
were arranged based on similarities. Clusters A through D
represent subsets of indistinguishable or related isolates. Of
the 60 MRSA isolates that were tested, the majority possessed
the type II cassette (57% [n  34]). All but one of these
samples had clustered by strain typing into cluster A or B, and
most had met the criteria for HA-MRSA. A MRSA isolate was
defined as health care associated if it was obtained 48 h after
hospital admission or if the patient had been hospitalized
within 2 years before the date of MRSA isolation. All 34 of the
SCCmec type II isolates were PVL negative (100%). The single
SCCmec type II sample that did not cluster within the two
groups (sample 59) was not related to any other isolates yet
was also PVL negative.
The subtype IVa cassette was identified in 37% of the iso-
lates (n  22). Three samples were identified as type IV (5%)
but did not subtype using these primer sets. No isolates be-
longed to subtype IVb. Twenty-three of these type IV samples
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grouped into cluster C or D, and most had been classified by
infection control as CA-MRSA. An isolate was determined to
be CA-MRSA when it had been obtained from a patient out-
side the hospital setting or within 48 h of hospital admission
and if it was from a person who had not been hospitalized
within 2 years before the date of MRSA isolation. Twenty-
three of the 25 SCCmec type IV isolates were PVL positive
(92%). Of the two type IV isolates that were PVL negative
(8%), one had subtype IVa and a genetic fingerprint substan-
tially different from those of the other type IV isolates. The
other type IV, PVL-negative isolate (sample 17) did not sub-
type and grouped within cluster C.
Antibiogram analysis showed that overall, the type II, PVL-
negative isolates demonstrated resistance to more antimicro-
bials than the type IV, PVL-positive isolates (Table 1). It
appeared that the purported CA-MRSA isolates were more
likely than the HA-MRSA strains to be susceptible to clinda-
mycin, levofloxacin, and moxifloxacin.
One sample typed as III (1.7%) and was also PVL negative.
This isolate did not fall within any of the major clusters, being
distinguished from cluster C by a distinct, unique band. Inter-
estingly, this isolate was resistant to more antimicrobials than
any other sample studied; it was susceptible only to linezolid,
rifampin, and vancomycin (data not shown). This strain may
FIG. 1. Dendrogram representation and virtual gel image of rep-PCR fingerprints from MRSA isolates. Percentages of similarity are shown at
the bottom left of the dendrogram. Clusters A, B, C, and D are shown along with the SCCmec type and PVL status.
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represent a MRSA clone with prolonged exposure to the hos-
pital setting, where the antibiotic selective pressure is high.
None of the 60 isolates tested as SCCmec type I.
The majority (57%) of the 23 SCCmec type IV, PVL-posi-
tive isolates were taken from nasal or rectal collections for the
purpose of MRSA screening upon admission. Other type IV,
PVL-positive isolates were from skin/wound/abscess (35%),
tracheal aspirate (4%), and CSF (4%) specimens. The type II,
PVL-negative isolates were recovered predominately from
skin/wound/abscess collections (65%), followed by nasal (20%),
blood (9%), rectal (3%), and CSF (3%) specimens. These
strains were generally recovered from sites with more invasive
disease than the sites from which type IV isolates were recov-
ered; however, our type IV patient population included many
asymptomatic carriers. Still, it is noteworthy that 43% of the
patients with what was determined to be CA-MRSA presented
with significant infection within the hospital setting. Conse-
quently, the data do not appear to indicate an association
between severity of infection and the presence of PVL. In fact,
many of the type IV strains characterized in this study repre-
sent colonizing strains as opposed to the type II infecting
strains. For the purpose of this study, the presence of the toxin
was used primarily as a marker for tracking community-asso-
ciated strains rather than as an indicator of invasive disease.
It is apparent that CA-MRSA has established itself within
the hospital environment. Community-associated strains that
are carried into hospitals have the ability to eventually cause
potentially serious infections. The presence of CA-MRSA within
the hospital setting also complicates efforts on behalf of infec-
tion control departments to distinguish CA-MRSA from HA-
MRSA infections. SCCmec typing and PVL analysis are valuable
adjunctive tools for evaluating the molecular epidemiology of
MRSA, further characterizing strains within the hospital as well
as those circulating in the community.
We thank George Killgore of the Centers for Disease Control and
Prevention for providing SCCmec controls.
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TABLE 1. Antimicrobial susceptibility profile comparison of
MRSA isolates with SCCmec types II and IV
Antimicrobial agent(s)
No. (%) of susceptible isolatesa
Type II (n  31) Type IV (n  19)
Sulbactam-ampicillin 0 (0) 0 (0)
Cefazolin 0 (0) 0 (0)
Clindamycin 18 (58) 18 (95)
Erythromycin 0 (0) 2 (11)
Gentamicin 30 (97) 18 (95)
Levofloxacin 0 (0) 11 (58)
Linezolid 30 (97) 19 (100)
Moxifloxacin 4 (13) 15 (79)
Oxacillin 0 (0) 0 (0)
Penicillin 0 (0) 0 (0)
Rifampin 31 (100) 19 (100)
Tetracycline 31 (100) 17 (89)
Trimethoprim-sulfamethoxazole 30 (97) 19 (100)
Vancomycin 31 (100) 19 (100)
a Data available for 50 of the 60 patients in the study.
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